Современные проблемы резистентности пневмотропных патогенов

1. Bartlett J.C., Mundy L.M. Community-acquired pneumonia. N. Engl. J. Med. 1995; 333: 1618–1624.

2. File T.M.Jr. Etiology and incidence of community-acquired pneumonia. Infect. Dis. Clin. Pract. 1996; 5: S127–S135.

3. Doern G.V., Pfaller M.A., Kugler K. et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from SENTERY antimicrobial surveillance program. Clin. Infect. Dis. 1998; 27: 764–770.

4. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing; Eleventh informational Suppl. M100–S11. Wayne, PA: NCCLS; 2001.

5. Sahm D.F., Thornsberry C., Mayfield D.C. et al. In vitro activities of broad spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations. J. Clin. Microbiol. 2002; 40: 669-674.

6. Jones M.E., Blosser!Middleton R.S., Critchley I.A. et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000–2001. Clin. Microbiol. Infect. 2003; 9: 590–599.

7. Sahm D.F., Weaver M.K., Flamm R.K. et al. Antimicrobial susceptibility in Streptococcus pneumoniae recovered from sinus specimens: results from 2000–2003 TRUST surveillance studies. In: 43rd Interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, USA. Sept. 14–17, 2003. Chicago; 2003. Poster C2–924.

8. Schito G.C., Debbia E.A., Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J. Antimicrob. Chemother. 2000; 46 (suppl. T1): 3–9.

9. Huff J., White A., Power E. et al. 10-year trends in penicillinand erythromycin-resistant S.pneumoniae for 5 European countries and the USA. The Alexander Project [abstract C21624]. In: Abstracts from the 42nd Interscience conference on antimicrobial agents and chemotherapy. San Diego, USA: American Society of Microbiology; 2002. 108.

10. Schito G.C. Is antimicrobial resistance also subject to globalization? Clin. Microbial. Infect. 2002; 8 (suppl. 3): 1–8.

11. Hsueh P.R. Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic usage in Taiwan. Clin. Microbiol. Infect. 2005; 11: 925–927.

12. McGee L., Klugman K.P., Wasas A. et al. The Antibiotic Surveillance Forum of South Africa. Serotype 19F multiresistant pneumococcal clone harboring two erythromycin resistance determinants [erm (b) and mef (a)] in South Africa. Antimicrob. Agents Chemother. 2001; 45: 1595–1598.

13. Marchese A., Ramirez M., Schito G.C., Tomasz A. Molecular epidemiology of penicillin-resistant Streptococcus pneumoniae isolates recovered in Italy from 1993–1996. J. Clin. Microbiol. 1998; 36: 2944–2949.

14. Corso A., Severina E.P., Petruk V.F. et al. Molecular characterization of penicillin-resistant Streptococcua pneumoniae isolates causing respiratory disease in the United States. Microb. Drug. Resist. 1998; 4: 325: 37.

15. Richter S.S., Heilmann K.P., Coffman S.L. et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994–2000. Clin. Infect. Dis. 2002; 34: 330–339.

16. Ho P.L., Yam W.C., Cheung T.K.M. et al. Fluoroquinolone resistance among Streptococcus pneumoniae in Hong Kong linked to the Spanish 23F clone. Emerg Infect Dis 2001; 7: 906–908.

17. McGee L., Goldsmith C.E., Klugman K.P. Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J. Antimicrob. Chemother. 2002; 49: 173–176.

18. Esposito S. Outpatient parenteral treatment of bacterial infections: the Italian model as an international trend? J. Antimicrob. Chemother. 2000; 45: 724–727.

19. Tice A.D. International outpatient parenteral antimicrobial therapy. Int. J. Clin. Pract. 2000; suppl. 115: 25–26.

20. Critchley I.A., Blosser!Middleton R.S., Jones M.E. et al. Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999–2000. Int. J. Antimocrob. Agents 2002; 20: 100–107.

21. Ho P.L., Yung R.W., Tsang D.N. et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: Results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 2001; 48: 659–665.

22. Chen D.K., McGreer A., de Azavedo J.C., Low D.E. for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 1999; 341: 233–239.

23. Jacobs M.R., Felmingham D., Appelbaum P.C., Gruneberg R.N. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 2003; 52: 229–246.

24. Ho P.L., Tse W.S., Tsang K.W. et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case control study. Clin. Infect. Dis. 2001; 32: 701–707.

25. Doern G.V., Brueggemann A.B., Pierce G. et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillinclavulanate: results of a national multicenter surveillance study. Antimicrob. Agents Chemother. 1997; 41: 292–297.

26. Blosser-Middleton R.S., Sahm D.F., Thornsberry C. et al. Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000–2001. Clin. Microbiol. Infect. 2003; 9: 431–436.

27. Low D.E. Antimicrobial drug use and resistance among respiratory pathogens in the community. Clin. Infect. Dis. 2002; 33 (suppl. 3): S206–S213.

28. Richter S.S., Brueggemann A.B., Huynh H.K. et al. A 19971999 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US Institutions. Int. J. Antimicrob. Agents 1999; 13: 99–107.

29. Sader H.S., Gales A.C., Granacher T.D. et al. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTERY antimicrobial surveillance program (1997–98). Braz. J. Infect. Dis. 2000; 4: 245–254.

30. Ohkusu K., Nakamura A., Sawada K. Antibiotic resistance among recent clinical isolates of Haemophilus influenzae in Japanace children. Diagn. Microbiol. Infect. Dis. 2000; 36: 249–254.

31. PROTEKT Study Database. Feb. 2001 (http://www.protekt.org).

32. Seki H., Kasahara Y., Ohta K. et al. Increasing prevalence of ampicillin-resistant, non-beta-lactamase-producing strains of Haemophilus influenzae in children in Japan. Chemotherapy 1999; 45: 15–21.

33. Felminghem D., Gruneberg R.N. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J. Antimicrob. Chemother. 2000; 45: 191–203.

34. Tee N.W., Lin R.V. Serotypes and antimicrobial resistance in Haemophilus influenzae in a hospital practice. Ann. Acad. Med. Singapore 1996; 25: 184–187.

35. Chang S.C., Hsieh W.C., Liu C.Y. High prevalence of antibiotic resistance of common pathogenic bacteria in Taiwan. The Antibiotic Resistance Study Group of the Infectious Disease Society of the Republic China. Diagn. Microbiol. Infect. Dis. 2000; 36: 107–112.

36. Козлов Р.С., Кречикова О.И., Сивая О.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России: результаты проспективного многоцентрового исследования (фаза А проекта ПеГАС-1). Клин. микробиол. и антимикроб. химиотер. 2002; 3: 267–277.

37. Grudinina S.A., Filimonova O.Y., Sidorenko S.V. Surveilance of antibacterial resistance in major pathogens of communityacquired respiratory tract infections in Moscow, Russia, 2004. In: 15th Congress of European Society Clinical Microbiology and Infections Diseases, Copenhagen, Denmark, April 2–5, 2005. Copenhagen; 2005, abstr. P1776.

38. Зубков М.Н., Гугуцидзе Е.Н., Ноников В.Е. и др. Роль Streptococcus pneumoniae и Haemophilus influenzae в этиологии острых пневмоний у лиц пожилого возраста. Журн. микробиол. 1984; 4: 67–70.

39. Hoban D.J., Doern V.G., Fluit A.C. et al. Waldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus unfluenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program 19971999. Clin. Infect. Dis. 2001; 32 (suppl. 2): 81–93.

40. Doern G.V., Heilmann K.P., Huynn H.K. et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob. Agents Chemother. 2001; 45: 1721–1729.

41. Чучалин А.Г., Синопальников А.И., Яковлев С.В. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике (пособие для врачей). Клин. микробиол. и антимикроб. химиотерапия. 2003; 3: 198–224.

42. Зубков М.Н. Moraxella (Branchamella) catarrhalis: роль в патологи человека, идентификация и антибиотикорезистентность. Инфекции и антимикроб. химиотер. 2001; 3: 38–41.

43. Catlin B.N. Branchamella catarrhalis an organism gaining respect as a pathogen. Clin. Microbiol. Rev. 1990; 3: 293–320.

44. Jorgensen J.H., Doern G.V., Maher L.A. et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 1990; 34: 2075–2080.

45. Macris M.H., Hartman N., Murray B. et al. Studies of the continuing susceptibility of group A streptococcal strains to penicillin during eight decades. Pediatr. Infect. Dis. J. 1998; 17: 377–381.

46. Horn D.L., Zabriskie J.B., Austrian R. et al. Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin. Infect. Dis. 1998; 26:1341–1345.

47. Lowbury E.J.L. Symposium on epidemiological risk of antibiotics. Hospital infections. Proc. R. Soc. Med. 1958; 51: 807–810.

48. Cornaglia G., Fontana R. Epidemiological survey of bacterial rasistance in upper respiratory tract infections in Italy. Int. J. Antimicrob. Agents 2000; 16: 259–262.

49. Melo!Cristino J., Fernandes M.L. Streptococcus pyogenes isolated in Portugal: macrolide resistance phenotypes and correlation with T types. Portuguese Surveillance Group for Study of Respiratory Pathogenes. Microb. Drug Resist. 1999; 5: 219–225.

50. Alos J.I., Aracil B., Torres C. et al. High prevalence of erythromycin-resostant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998, Spanish group for the study of Infection in the Primary Health Care Setting. J. Antimicrob. Chemother. 2000; 45: 605–609.

51. Baquero F., Garcia!Rodriguez J.A., de Lomas J.C., Aguilar L. Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: results of 1-year (1996–1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogenes. Antimicrob. Agents Chemother. 1999; 43: 178–180.

52. Kaplan E.L., Johnson D.R., Del Rosario M.C., Horn D.L. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr. Infect. Dis. 1999; 18: 1069–1072.

53. de Azavedo J.C., Yeung R.H., Bast D.J. et al. Prevalence and mechnisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob. Agents Chemother. 1999; 43: 2144–2147.

54. York M.K., Gibbs L., Brooks G.F. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J. Clin. Microbiol. 1999; 37: 1727–1731.

55. Козлов Р.С., Сивая О.В., Шпынев Л.В. и др. Антибиотикорезистентность Streptococcus pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-1. Клин. микробиол. антимикроб. химиотер. 2005; 2: 154–166.

56. Сидоренко С.В. Проблемы этиотропной терапии внебольничных инфекций дыхательных путей. Consilium medicum 2002; 1: 4–10.

57. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur. Respir. J. 2002; suppl. 36: 20s–27s.

58. Centers for Disease Control and Prevention. Four pediatric death from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997–1999. J. A. M. A. 1999; 282: 1123–1125.

59. Torres A., Woodhead M., eds. Pneumonia. Eur. Respir. Monograph. 1997; 2: Monogr. 3: 262.

60. Зубков М.Н., Самойленко В.А., Гугуцидзе Е.Н. и др. Микробиологические аспекты этиологии и антимикробной терапии бронхолегочной инфекции при муковисцидозе у взрослых. Пульмонология 2001; 3: 38–41.

61. Wu S., Piscitelli C., deLancastre H., Tomasz A. Tracking the evolutionary origin of the meticillin-resistant gene: cloning and sequencing of a gomologue of mecA from methicillin susceptible strain of Staphylococcus sciuri. Microb. Drug Resist. 1996; 2: 435–41.

62. Opal S.M., Medeiros A.A. Molecular mrchanisms of antibiotic resistance in bacteria. In: Mandell G.L., Bennett J.E., Dolin R., eds. Principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingstone; 2004. 253–270.

63. Страчунский Л.С. β-лактамазы расширенного спектра быстро растущая и плохо сознаваемая угроза. Клин. микробиол. и антимикроб. химиотер. 2005; 1: 92–96.

64. Эйдельштейн М.В., Страчунский Л.С. и др. Динамика распространенности и чувствительности БЛРС-продуцирующих штаммов энтеробактерий к различным антимикробным препаратам в ОРИТ России. Клин. микробиол. и антимикроб. химиотер. 2005; 7: 233–236.

65. Chambers H. The changing epidemiology of staphylococcus aureus? Emerg. Inf. Dis. 2001; 7: 178–182.